p53 activation is dependent on the formation of PML nuclear bodies in gastric and liver 64 cancer cells. Mechanistically, XPO1 inhibition induces relocalization of autophagy 65 adaptor protein p62 (SQSTM1), recruiting p53 for activation in PML nuclear bodies. 66
Abstract 30
The abnormal proliferation of cancer cells is driven by deregulated oncogenes or tumor 31 suppressors, of which the cancer vulnerable genes are attractive therapeutic targets. 32
Targeting mislocalization of oncogenes and tumor suppressors resulting from aberrant 33 nuclear export is effective for inhibiting growth transformation of cancer cells. We 34 performed a CRISPR-Cas9 screening in a unique model of matched primary and 35 oncogenic KSHV-transformed cells, and identified genes that were pro-growth and 36 growth-suppressive of both cells, of which exportin XPO1 was demonstrated to be 37 critical for the survival of transformed cells. Using XPO1 inhibitor KPT-8602 and by 38 siRNA knockdown, we confirmed the essential role of XPO1 in cell proliferation and 39 growth transformation of KSHV-transformed cells, and cell lines of other cancers 40 including gastric cancer and liver cancer. XPO1 inhibition induced cell cycle arrest 41 through p53 activation but the mechanism of p53 activation differed among different 42 types of cancer cells. p53 activation depended on the formation of PML nuclear bodies 43 in gastric cancer and liver cancer cells. Mechanistically, XPO1 inhibition induced 44 relocalization of autophagy adaptor protein p62 (SQSTM1), recruiting p53 for activation 45 in PML nuclear bodies. Taken together, we have identified novel pro-growth and 46 growth-suppressive genes of primary and cancer cells, and demonstrated XPO1 as a 47 vulnerable target of cancer cells. XPO1 inhibition induces cell arrest through a novel 48 PML-and p62-dependent mechanism of p53 activation in some types of cancer cells. 49
Importance 50
Using a model of oncogenic virus KSHV driven cellular transformation of primary cells, 51
we have performed a genome-wide CRISPR-Cas9 screening to identify vulnerable 52 genes of cancer cells. This screening is unique in that this virus-induced oncogenesis 53 model does not depend on any cellular genetic alterations, and has matched primary 54 and KSHV-transformed cells, which are not available for similar screenings in other 55 types of cancer. We have identified genes that are both pro-growth and growth-56 suppressive in primary and transformed cells, some of which could represent novel 57 proto-oncogenes and tumor suppressors. In particular, we have demonstrated exportin 58 XPO1 as a critical factor for the survival of transformed cells. Using a XPO1 inhibitor 59 KPT-8602 and by siRNA-mediated knockdown, we have confirmed the essential role of 60 XPO1 in cell proliferation and growth transformation of KSHV-transformed cells, as well 61 as gastric and liver cancer cells. XPO1 inhibition induces cell cycle arrest by activating 62 p53 but the mechanism of p53 activation differed among different types of cancer cells. 63
Introduction 73
The malfunction of nuclear transport, which shuttles proteins between cytoplasm 74 and nucleus, often leads to mislocalization of oncogenes and tumor suppressor proteins 75 in cancer cells (1) . Indeed, numerous proteins involved in cancer including p53, APC, 76
Retinoblastoma (Rb), NFAT and β-catenin are abnormally localized in cancer cells. The 77 consequence of these dysfunctions is either over-activation of oncogenes, or 78 inactivation of tumor suppressor proteins, resulting in uncontrolled cell proliferation and 79 growth transformation(2). 80
Unlike passive diffusion of metabolites, shuttling of proteins between nucleus and 81 cytoplasm is an active, highly regulated receptor-mediated process. The nuclear pore 82 complex (NPC) is a supramolecular structure composed of more than 30 nucleoporins 83 interacting with importins and exportins within the NPC channel. The directionality of the 84 transport depends on the distribution of GTP-or GDP-bound GTPase, the Ran protein, 85 in both cytoplasmic and nucleic compartments(3). Indeed, while importins bind to their 86 cargo proteins in cytoplasm and release them in nucleus upon binding of RanGTP, 87 exportins bind to cargos in nucleus only in the presence of RanGTP and release them in 88 cytoplasm upon Ran-driven GTP hydrolysis(4). 89
The exportin family consists of 7 members including XPO1 (CRM1), XPO2 90 (CSE1L), XPO3 (XPOt), XPO4, XPO5, XPO6 and XPO7. While XPO1, XPO2, XPO4, 91 XPO6 and XPO7 primarily mediate the export of cargo proteins, XPO3 and XPO5 are 92 involved in the transport of tRNAs and precursor microRNAs (pre-miRNAs), 93 respectively. XPO1, the major protein export receptor, is also associated with the 94 nuclear export of mRNAs and rRNAs(5). 95
Mechanistically, XPO1 interacts with the nucleoporins NUP214 and NUP88 96 inside the NPC and exports proteins containing XPO1-specific nuclear export signal 97 (NES), which are short leucine-rich sequences. Several tumor suppressor proteins and 98 oncogenes display XPO1-specific NES(6). Consequently, XPO1 dysregulation indirectly 99 regulates cellular functions including cell proliferation and cellular transformation, 100 apoptosis, and chromosome segregation(2). Particularly, XPO1 is upregulated in 101 ovarian carcinoma, glioma, osteosarcoma, pancreatic, cervical and gastric cancers, 102 which induces abnormal accumulation of the tumor suppressor proteins Rb, APC, p53, 103 p21 and p27 in the cytoplasm, leading to their losses of nuclear functions(2). On the 104 other hand, inhibition of XPO1 by RNA interference or with inhibitors, such as 105
Leptomycin B or selective inhibitors of nuclear export (SINE), prevents cellular 106 transformation and tumorigenesis in numerous cancer models. Hence, XPO1 has 107 become a promising target in cancer therapy (7) . 108
Nuclear bodies (NBs) are membraneless structures within the nucleus involved in 109 multiple pathways of genome maintenance. Among them, promyelocytic leukemia 110 protein nuclear bodies (PML-NBs) are involved in DNA repair, DNA damage response, 111 telomere homeostasis, and p53-associated apoptosis and cell cycle arrest(8). Of the 112 various biological consequences of XPO1 inhibition, several groups observed the 113 retention of p53, the most described tumor suppressor, in the nucleus, enhancing p53-114 mediated tumor suppressor activity(8). Indeed, activation of p53 induces cell cycle 115 arrest and apoptosis in many types of cancer cells. Particularly, inside the nucleus, p53 116 colocalizes and interacts with PML-NBs, which serve as p53-coactivator(9). PML 117 knockout impairs p53-dependent apoptosis, p53-mediated transcriptional activation, as 118 well as induction of p53 target genes such as Bax and p21(9). Therefore, PML-NBs may 119 play a significant role in apoptosis and cancer. Nevertheless, the underlying molecular 120 mechanism mediating PML-dependent p53 activation is still unclear. 121
The development of new genome engineering technologies has enabled the 122 identification of oncogenes and tumor suppressors in cancer cells in vitro and in vivo(10, 123 11). Particularly, the clustered regularly interspaced short palindromic repeats 124 (CRISPR)-CRISPR-associated (Cas) proteins system, adapted to mammalian cells 125 based on a mechanism of adaptive immunity of bacteria and archea, enhances the 126 accessibility of genome manipulation by allowing the targeting of genes with specific 127
RNA sequences(12). Briefly, CRISPR relies on Cas9 guided by sgRNAs (CRISPR 128
RNAs) to induce loss of function (LOF) mutations via frameshifts in the coding region, 129 leading to gene inactivation. CRISPR-Cas9 system has enabled different types of 130 genetic modifications, such as gene disruption or transcriptional activation. Several 131 types of biological screens based on the CRISPR-Cas9 system have already been 132 carried out to identify viral restriction factors, oncogenes, and tumor suppressors, as 133 well as develop T-cell immunotherapies. 134
In this study, by performing a genome-wide CRISPR-Cas9 screening of cells 135 transformed by an oncogenic virus Kaposi's sarcoma-associated herpesvirus (KSHV), 136
we have identified cellular genes that are essential for cellular transformation(13). 137
Briefly, a CRISPR pooled libraries containing sgRNAs that specifically target all known 138 cellular genes were transduced into Cas9-expressing KSHV-transformed primary rat 139 mesenchymal embryonic stem cells (KMM) and control primary rat mesenchymal stem 140 cells (MM)(13). Genomic DNA from surviving MM and KMM cells at day 1, 4, 11 and 21 141 post-transduction were collected and sequenced, and the results were analyzed for the 142 gain or loss of sgRNAs. We identified the exportin family members XPO1, XPO2, 143 XPO3, XPO5 and XPO7 as the essential factors involved in the survival of KMM cells. 144
We confirmed the essential role of XPO1 in cell proliferation and growth transformation 145 using cell lines of other types of cancer, including AGS derived from gastric cancer and 146 HUH7 derived from liver cancer. We showed that inhibition of XPO1 by siRNAs or with a 147 XPO1 inhibitor KPT-8602 blocked cell proliferation and growth transformation by 148 inducing p53-mediated cell cycle arrest in all types of cancer cells tested. However, we 149 found that the mechanism mediating p53 activation differed among different types of 150 cancer cells. In AGS and HUH7 cells, p53 activation was correlated with nuclear 151 accumulation of autophagy adaptor protein p62 (SQSTM1), which was colocalized with 152 We first generated MM and KMM cells stably expressing Cas9 by lentiviral 168 transduction following by positive selection with blasticidin for 1 week. Interestingly, we 169 repeatedly observed weaker expression of Cas9 protein in MM than KMM cells in 170 multiple experiments (Supplemental Fig. 1A ). This was likely due to a higher rate of cell 171 proliferation of KMM cells than MM cells, often leading to higher expression levels of 172 genes(13, 15). Despite the differential levels of Cas9 expression, we observed efficient 173 inhibition of the endogenous SIRT1 expression after lentiviral transduction of sgRNAs 174 targeting SIRT1 in both Cas9-expressing MM and KMM cells (Supplemental Fig. 1B) . 175
Importantly, Cas9 expression did not affect the efficiency of colony formation of KMM 176 cells in softagar (Supplemental Fig. 1C ). As expected, Cas9-expressing MM cells did 177 not form any colony in softagar(13). These results indicate that the Cas9-expressing 178 MM and KMM cells can be used for identifying essential cellular genes that mediate 179 growth transformation. 180
We then generated a library of sgRNAs targeting 19,840 genes of the rat 181 genome, each with 3 independent sgRNAs. Cas9-expressing MM and KMM cells were 182 transduced with the lentiviral sgRNA library and selected for 3 days with puromycin. The 183 cultures were then switched to normal medium without any selection and cell samples 184 were collected at day 1, 4, 11 and 21, and subjected to DNA sequencing to determine 185 the gain and loss sgRNAs over time ( Fig. 1A ). Cumulative frequencies of sgRNAs were 186 analyzed at day 1, 4, 11, and 21 post-transduction in MM and KMM cells ( Fig. 1B) . 187
Compared to day 1, we observed a progressive shift to the left in the curves at day 4, 188 11, and 21 post-transduction, indicating depletion of a subset of sgRNAs. By assessing 189 the global gene vulnerability in at day 4, 11, and 21 post-transduction, we observed a 190 lower abundance of essential genes, displaying as negative CRISPR scores, in KMM 191 than in MM cells, suggesting that KMM cells had higher survival rates than MM cells 192 ( Fig. 1B) , which was also shown by the CRISPR scores of individual genes (Fig. 1C) . translation, which were significantly higher in KMM than in MM cells, confirming that MM 198 cells were more susceptible to gene disruption than KMM cells ( Fig. 1D) . 199
200

Identification of essential genes and pathways of KSHV-transformed cells by 201
CRISPR-Cas9 screening. Since essential genes are likely to encode key regulators of 202 cellular processes involved in the survival of cancer cells, several studies investigated 203 the overlapping of essential genes across different cancer cell lines by CRISPR-Cas9 204 screening(17). Therefore, we correlated results of MM and KMM cells with those of 205 previous studies in chronic myeloid leukemia cell lines (KBM7 and K562) and Burkitt's 206 lymphoma cell lines (Raji and Jiyoye). We found a high degree of overlap in gene 207 essentiality between KSHV-transformed cells and other types of cancer cells (R 2 ≥0.29) 208 ( Fig. 2A ). On the other hand, the correlation of essential genes remained low between 209 the primary MM cells and other types of cancer cells (R 2 ≤0.09). 210
We next classified the 19,840 genes based on CRISPR scores. For each type of 211 cells, we first selected genes with CRISPR scores that were statistically different at day 212 21 over day 1, then between KMM and MM cells, and obtained 9 groups of genes (Fig. 213 2B and Table S1 ). Group 1 consisted of 11 genes that had significant increase in 214 CRISPR score for KMM cells but significant decrease in CRISPR score for MM cells; 215 Group 2 consisted of 680 genes that had significant increase in CRISPR score for KMM 216 cells but no significant change in CRISPR score for MM cells; Group 3 consisted of 51 217 genes that had significant increases in CRISPR score for both KMM and MM cells; 218 Group 4 consisted of 402 genes that had no significant change in CRISPR score for 219 KMM cells but had significant decrease in CRISPR score for MM cells; Group 5 220 consisted of 16,558 genes that had no significant change in CRISPR score for both 221 KMM and MM cells; Group 6 consisted of 552 genes that had no significant change in 222 CRISPR score for KMM cells but had significant increase in CRISPR score for MM 223 cells; Group 7 consisted of 314 genes that had significant decreases in CRISPR score 224 for both KMM and MM cells; Group 8 consisted of 1,259 genes that had significant 225 decrease in CRISPR score for KMM cells but had no significant change in CRISPR 226 score for MM cells; and Group 9 consisted of 13 genes that had significant decrease in 227 CRISPR score for KMM cells but had significant increase in CRISPR score for MM 228
cells. 229
Of these 9 groups, genes in Group 8 were likely essential or pro-oncogenic for 230 KMM cells but not for MM cells, of which, 18 genes had CRISPR score ratios of <-5 (-32 231 fold) at day 21 over day 1 for KMM cells, including Naa38, Rpl9_like, Rpl23a, Spcs3, 232
Hspa14_like, Nfyb, Eif2b2, Mrpl55, Pold1, Nup43, Lin52, Csnk1a1, Aldoa, Rpl6, Ddx6, 233
Wdr74, Rars and Cnot1. Genes in Group 2 were likely growth-suppressive for KMM 234 cells but not MM cells. On the other hand, genes in Group 4 were likely essential or pro-235 growth for MM cells but not KMM cells while genes in Group 6 were likely growth-236 suppressive for MM cells but not KMM cells, suggesting that KSHV might target these 237 two sets of genes to allow the transformed cells to overcome the essential or growth-238 suppressive functions of these genes, respectively. 239
We determined the molecular pathways that were significantly depleted and 240 enriched in KMM over MM cells (day 21 vs day 1) by Ingenuity Pathway Analysis (IPA) 241 (Supplemental Table 2 and 3). We found that the EIF2 pathway, the regulation of eIF4 242 and p70S6K, and the mTOR pathway were the top 3 depleted pathways in KMM cells, 243 compared to MM cells, highlighting their roles in the survival of the transformed cells 244 whereas XPO7 sgRNA counts significantly increased in KMM cells indicating its putative 258 anti-survival effect in the transformed cells (Supplemental Fig. 3 ). In addition, MM cells 259 were sensitive to XPO1, XPO2 and XPO5 knockout (Supplemental Fig. 3 ). Numerous 260 inhibitors have been developed for the main exportin member, XPO1. Some of these 261 inhibitors are currently in clinical trials for different types of cancer(19-21). Hence, we 262 decided to focus on this exportin. 263
Since XPO1 is upregulated in numerous types of cancer(22), we first examined 264 XPO1 expression in KMM cells compared to MM cells. We observed 3-fold higher 265 expression level of XPO1 in KMM than MM cells at mRNA level ( Fig. 3A) , which was 266 confirmed at protein level ( Fig. 3B ). Because KMM cells are latently infected by KSHV, 267 expressing viral latent genes LANA, vFLIP, vCyclin and the miRNA cluster(13, 23), we 268 examined the roles of these genes in XPO1 expression. Deletion of either vCyclin or the 269 miRNA cluster but not vFLIP abolished XPO1 upregulation ( Fig. 3A and 3B ). Because 270 LANA is essential for KSHV episome persistence, we were not able to obtain cells 271 latently infected by the LANA mutant(14). However, overexpression of LANA in MM 272 cells did not alter XPO1 expression (results not shown). By complementing cells 273 infected by the miRNA cluster deletion mutant (miR) with individual miRNAs, we found 274 that pre-miR-K3 mediated XPO1 upregulation ( Fig. 3C ). Hence, both vCyclin, a 275 homologue of the cellular Cyclin D2(15), and pre-miR-K3, which activates the Akt 276 pathway(24), not only promote cell cycle progression and facilitate G1/S phase 277 transition, respectively (15, 23), but also cause XPO1 upregulation. 278
We performed RNA interference knockdown to confirm the results obtained in 279
CRISPR-Cas9 screening in KMM cells as well as cell lines of other types of cancer 280
including AGS and HUH7 derived from gastric and liver cancers, respectively. The role 281 of XPO1 in gastric cancer has not been examined before and has only been minimally 282 examined in liver cancer(25). Knockdown of XPO1 decreased cell proliferation in KMM, 283 AGS and HUH7 cells but had no effect on the primary MM cells ( Fig. 3D-F HUH7 cells (Fig. 4A ), suggesting different responses of these cells to KPT-8602. In 296 parallel, we observed an activation of the p53 pathway as shown by the increase of 297 phospho-p53 in KMM, AGS and HUH7 cells but not MM cells after treatment with 1 µM 298 of KPT-8602 for 24 h (Fig. 4B ). p53 activation has been shown to be dependent on 299 PML-NBs within the nucleus. Interestingly, both MM and KMM cells had strong nuclear 300 PML staining as well as cytoplasmic staining with some cells showing staining pattern 301 similar to PML-NBs, and KPT-8602 treatment did not alter the PML staining pattern in 302 these cells (Fig. 4C) . These results indicated that PML-NBs were unlikely to mediate 303 p53 activation in KMM cells. In contrast, AGS cells had no nuclear PML staining and 304 only some HUH7 cells had weak nuclear PML staining, none of which showed staining 305 pattern of PML-NBs (Fig. 4C ). However, strong nuclear staining with PML-NBs pattern 306 was observed following KPT-8602 treatment in AGS and HUH7 cells (Fig. 4C) . 307
Significantly, siRNA knockdown of PML (Fig. 4D) , which disrupted PML-NBs, inhibited 308 KPT-8602 induced p53 phosphorylation in AGS and HUH7 cells, highlighting the 309 essential role of PML-NBs in p53 activation in these cells (Fig. 4E) . for 24 h increased the expression level of p62 in AGS and HUH7 cells (Fig. 5A) . 316
Interestingly, we observed nuclear translocation and accumulation of p62, which was 317 colocalized with p53 in AGS and HUH7 cells after KPT-8602 treatment (Fig. 5B) . 318
Furthermore, p62 was colocalized with PML-NBs in AGS and HUH7 cells following 319 XPO1 inhibition, which was consistent with the hypothesis of formation of hybrid bodies 320 (Fig. 6A ). The expression level of p62 was also increased in KMM cells but not in MM 321 cells (Fig. 5A ). However, we did not observe nuclear translocation and accumulation of 322 p62 in MM and KMM cells, and there was no nuclear colocalization of p53 with p62 in 323 these cells (Fig. 5B ). Consistent with these results, there was no obvious nuclear 324 colocalization of p62 with PML-NBs in MM and KMM cells (Fig. 6A ). These results 325 indicated that p62 was unlikely to be involved in p53 activation following XPO1 inhibition 326 in KMM cells. 327
To investigate the role of p62 in p53 activation in AGS and HUH7 cells, we 328 performed knockdown of p62 in AGS and HUH7 cells (Fig. 6B ). Knockdown of p62 329 abolished p53 activation in AGS cells and significantly decreased p53 activation in 330 HUH7 cells following treatment with KPT-8602 ( Fig. 6C) . These results indicate an 331 essential role of p62 accumulation in XPO1 inhibition-induced p53 activation in PML-332
NBs in AGS and HUH7 cells. highlighted the dependence of IRF4 and MDM2 pathways in PEL survival. They also 367 showed the dependency of PEL cells on cyclin D2 and c-Flip. In our study, we have 368 used matched primary MM cells as controls and identified 1,259 genes (Group 8) that 369 are essential for maintaining the proliferation of KMM cells, of which, 18 genes had 370 CRISPR score ratios of <-5 (-32 fold) at day 21 over day 1 for KMM cells (Fig. 2) . The current study has identified XPO1 as a critical factor for the proliferation of 381 KSHV-transformed cells. We confirmed the essential role of XPO1 in cell proliferation 382 and cellular transformation of cell lines derived from gastric and liver cancers (Fig. 3) . and XPO1 inhibitor is likely to improve the efficacy of cancer therapy. 407
The mechanism of XPO1 upregulation in cancer cells is still not well understood. 408
Chromosomal translocations, and mutations or gain of copies of XPO1 gene could 409 explain XPO1 overexpression. Indeed, a recurrent mutation in codon 571 of XPO1 gene 410 has been reported in acute lymphoblastic leukemia (ALL) and in an adult acute myeloid 411 leukemia (AML) with CBL syndrome displaying XPO1 overexpression(39, 40). 412
Moreover, Myc and p53, often found modulated in cancer cells, have been shown to 413 positively and negatively alter the expression of XPO1, respectively(41). Finally, a copy 414 number gain in the XPO1 locus was also observed in patients affected by primary 415 mediastinal B-cell lymphoma (PMBL) and diffuse large B-cell lymphoma (DLBCL)(42, 416 43). We observed increased XPO1 expression in KMM cells compared to MM cells, and 417 that both vCyclin and pre-miR-K3 mediated XPO1 upregulation (Fig. 3A-3C ). It would be 418 interesting to investigate the effect of cell cycle progression on XPO1 upregulation. 419 SINE compounds have been used to treat several types of cancer, among them, 420
KPT-330 is currently in Phase 1 and 2 clinical trials in numerous solid and hematologic 421 malignancies with and without in combination with other chemotherapeutic agents, and 422 has shown promising results(33). To decrease adverse side effects, a second 423 generation of SINE compounds including KPT-8602 with improved tolerability have 424 been developed and tested in clinical trials(44). In this report, we have shown that KPT-425 8602 inhibits the cell proliferation and cellular transformation of KMM, AGS and HUH7 426 cells (Fig. 3) , confirming the anti-cancer effect of SINE family. Indeed, KPT-8602 has 427 been shown to inhibit the proliferation of leukemia cells derived from ALL in vitro and 428 increase the animal survival rate in ALL xenograft models(45). 429 SINE compounds can block XPO1-mediated export, and therefore cause 430 mislocalization of tumor suppressors or oncoproteins, and decrease the survival of 431 cancer cells (1) . A previous study highlighted the nuclear accumulation of p21, p27 and 432 FOXO proteins after treatment with SINE compound S109 in colorectal cancer cells(46). 433
Recently, KPT-330 has been shown to induce p53 and p21 retention within the nucleus 434 in gastric cancer cells(47). In our report, we have observed cell cycle arrest associated 435 with p53 activation in KMM, AGS and HUH7 cells after KPT-8602 treatment. However, 436
we have found that different types of cancer cells respond differently to this inhibitor with 437 KMM cells manifesting G2/M arrest, and AGS and HUH7 cells manifesting G0/G1 arrest 438 (Fig. 4A ). Consistent with these results, the mechanism mediating p53 activation in AGS 439 and HUH7 cells is different from that in KMM cells. We have observed p53 nuclear 440 accumulation in AGS and HUH7 cells but not KMM cells after KPT-8602 treatment (Fig.  441   5B) . 442 PML-NBs recruit a variety of proteins and modulate their posttranslational 443 modifications. Particularly, p53 and its regulators (ARF, HIPK2, CBP, MDM2, SIRT1 444 and MOZ) traffic through PML-NBs, suggesting that these nuclear bodies could regulate 445 p53 activation by posttranslational modifications(48). Indeed, disruption of PML-NBs 446 inhibits p53 activation and induces expression of its downstream genes, such as Bax 447 and p21(9, 49, 50); however, the underlying mechanism remains unclear. Interestingly, 448
we have confirmed that p53 nuclear accumulation depends on the formation of PML-449
NBs after XPO1 inhibition in AGS and HUH7 cells ( Fig. 4C-E) . On the other hand, p53 450 activation in KMM after XPO1 inhibition does not depend on the formation of PML-NBs, 451 which remains to be further explored. 452
Other NBs have been identified in the nucleus, and some studies suggested 453 possible fusion events among them, forming hybrid NBs(51). Interestingly, XPO1 is 454 involved in the formation of CRM1-nucleolar bodies (CNoBs), and its inhibition by XPO1 455 inhibitor Leptomycin B disrupts CNoBs(52). Another type of NBs involved with p62 456 (SQSTM1) was identified by imaging(26). p62 protein is mostly described as a scaffold 457 cytoplasmic protein involved in autophagy processes by interacting with LC3, and 458 therefore mediating the recruitment of LC3 to poly-ubiquitinated protein aggregates to 459 form autophagosome in the cytoplasm(53). Unlike its cytoplasmic function, the role of 460 p62 within the nucleus is still not well understood. While PML-NBs are ubiquitous, 461
CNoBs and p62-NBs are stress-induced. It has been reported that p62-NBs are 462 colocalized with PML-NBs upon inhibition of CNoBs(51), highlighting the role of nuclear 463 p62 in the recruitment of poly-ubiquitinated proteins to PML-NBs(26). 464
The role of p62 in cancer development is still controversial(54). The expression 465 level of p62 can be increased in cancer cells, and its overexpression has been shown to 466 enhance cellular transformation through the activation of NRF2, mTORC1 and c-Myc 467 pathways in liver cancer cells, independent of the autophagy pathway(55). On the other 468 hand, in a non-tumorigenic environment, p62 attenuates inflammation and fibrosis(56), 469 and p62 loss has been shown to increase tumorigenesis in epithelial cells(57). 470
In this study, we have demonstrated the essential role of p62 in the activation of 471 p53 tumor suppressor after XPO1 inhibition in AGS and HUH7 cells ( Fig. 5 and 6 ). We 472 have observed nuclear accumulation of p62, which is colocalized with p53 after XPO1 473 inhibition in AGS and HUH7 cells. In parallel, we have observed colocalization of p62 474 with PML-NBs, hence enforcing the hypothesis of formation of PML-p62 hybrid NBs in 475 stress conditions(26). Finally, we have demonstrated for the first time that nuclear 476 accumulation of p62 is required for p53 phosphorylation and activation within the PML-477
NBs after KPT-8602 treatment in in AGS and HUH7 cells, demonstrating the indirect 478 role of p62 in regulating the function of p53 in these cancer cells. Interestingly, while 479 XPO1 inhibition causes an increase of p62 level in KMM cells, it neither leads to p62 480 nuclear accumulation nor mediates p53 activation ( Fig. 5 and 6 ). It would be interesting 481 to investigate whether the increase of p62 level after XPO1 inhibition contributes to the 482 Rat sgRNA library cloning. Rat sgRNA library cloning was carried out as previously 492 described(58). This sgRNA library consists in a library of 59,520 unique sgRNAs 493 targeting 19,840 coding genes, each with 3 independent sgRNAs, and 10 non-targeting 494 sgRNAs, for a total of 59,530 sgRNAs. Specifically, we carefully chose three target sites 495
for each gene to cover most common exon in transcript variants ranging from 3% to 496 70% in coding sequence (CDS) region from the rat genome (Rattus novegicus; Rnor 5.0 497 version). Furthermore, we chose the target sites by avoiding potential off-target effects 498 and in-frame mutations using Cas-OFFinder(59) and Cas-Designer(60) 499 (http://www.rgenome.net/). 500 501 Lentiviral production of the sgRNA library. Lentiviral production was carried out as 502 previously described(61, 62). Briefly, HEK293T cells, were seeded at ~40% confluence 503 one day before transfection in DMEM supplemented with 10% serum. One-hour prior to 504 of 100 µl was diluted in 4 ml of OptiMEM, and after 5 min, it was added to the mixture of 508 plasmid DNAs, incubated for 20 min and then added to the cells. Media was refreshed 509 after 6 h and collected after 3 days. The supernatant was centrifuged at 3,000 rpm at 510 4°C for 10 min to pellet cell debris, filtered (0.45 µm), and concentrated by 511 ultracentrifugation (Beckmann) at 24,000 rpm for 2 h at 4°C. The virus preparation was 512 finally resuspended overnight at 4°C in DMEM medium, aliquoted and stored at -80°C. 513 514 Lentiviral transduction of the sgRNA library. Lentiviral transduction was carried out 515 as previously described(61). Cells were transduced with the shRNA library via 516 spinfection at a MOI of 0.3 in full DMEM medium supplemented with 10% fetal bovine 517 serum, 4 mM L-glutamine, and 10 µg/ml penicillin and streptomycin in the presence of 518 10 µg/ml of polybrene. Flasks containing cells were centrifuged at 2,000 rpm for 2 h at 519 37°C. After the spin, media was removed and fresh DMEM media was added to the 520 cells. 521 522 Genome DNA sequencing. Genome DNA sequencing was carried out as previously 523 described(10). Genomic DNA was extracted using QiAMP kit (Qiagen) and PCR was 524 performed in two steps. First, the input genomic DNA was amplified in order to achieve 525 Immunofluorescence assay. Cells were fixed in methanol for 10 minutes at room 550 temperature and processed for antibody staining as previously described(63). 551
Immunostaining was performed using anti-p62 antibody (CST), anti-PML antibody 552 and Nanjing Medical University (KY101RC1710 to C. Lu). We thank members of Dr. 580
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